ImmuPharma PLC | Ownership
Companies that own ImmuPharma PLC
Hargreaves Lansdown Stockbrokers Ltd.
13,122,000
9.41%
3,115,000
0.02%
06/01/2018
Hargreaves Lansdown Asset Management Ltd.
4,573,000
3.28%
1,002,000
0.02%
06/01/2018
Société Générale Gestion SA
3,935,675
2.82%
-176,992
0.01%
06/01/2018
JPMorgan Securities Plc (Market-Maker)
2,203,000
1.58%
2,109,000
0.04%
06/01/2018
Aviva Investors Global Services Ltd.
2,086,964
1.5%
-8,053,334
0%
04/20/2018
Bank J. Safra Sarasin AG (Investment Management)
1,818,083
1.3%
-589,693
0.02%
06/01/2018
Walker Crips Stockbrokers Ltd.
1,793,000
1.29%
-1,103,000
0.02%
06/01/2018
HSBC Global Asset Management (UK) Ltd.
1,622,000
1.15%
347,000
0%
06/01/2018
Goldman Sachs (US) (Market-Maker)
1,298,000
0.93%
1,298,000
0.04%
06/01/2018
Barclays Bank Plc (Private Banking)
1,047,000
0.75%
0
0%
06/01/2018
| Address |
50 Broadway
London Greater London SW1 H0RG
United Kingdom
|
|
Employees
|
- |
| Website |
http://www.immupharma.com |
| Updated |
07/08/2019 |
| ImmuPharma Plc engages in the research, development, and commercialisation of pharmaceutical products. Its drug candidate, Lupuzor, is a potential treatment for the autoimmune chronic inflammatory disease lupus. The company was founded by Richard Warr and Dimitri F. |
